Shares of Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) dropped 1.9% on Tuesday . The company traded as low as C$3.05 and last traded at C$3.10, approximately 2,600 shares were traded during mid-day trading. A decline of 89% from the average daily volume of 23,749 shares. The stock had previously closed at C$3.16.
Separately, Roth Capital reissued a “buy” rating on shares of Aptose Biosciences in a report on Thursday, May 23rd.
The business has a fifty day simple moving average of C$3.48 and a two-hundred day simple moving average of C$2.87. The company has a quick ratio of 10.99, a current ratio of 11.27 and a debt-to-equity ratio of 5.06. The company has a market cap of $179.09 million and a P/E ratio of -5.22.
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Recommended Story: How do analysts define an oversold condition?
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.